Squarepoint’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13,567
| Closed | -$171K | – | 4566 |
|
|
2026
Q1 | $171K | Sell |
13,567
-52,399
| -79% | -$702K | ﹤0.01% | 3989 |
|
|
2025
Q4 | $1.04M | Buy |
+65,966
| New | +$838K | ﹤0.01% | 2569 |
|
|
2025
Q1 | – | Sell |
-11,558
| Closed | -$66.5K | – | 4797 |
|
|
2024
Q4 | $66.5K | Buy |
+11,558
| New | +$111K | ﹤0.01% | 4793 |
|
|
2024
Q1 | – | Sell |
-106,403
| Closed | -$1M | – | 4168 |
|
|
2023
Q4 | $1M | Buy |
106,403
+78,922
| +287% | +$735K | ﹤0.01% | 2519 |
|
|
2023
Q3 | $307K | Buy |
+27,481
| New | +$443K | ﹤0.01% | 3144 |
|
|
2023
Q2 | – | Sell |
-9,533
| Closed | -$386K | – | 3670 |
|
|
2023
Q1 | $386K | Sell |
9,533
-4,285
| -31% | -$205K | ﹤0.01% | 2438 |
|
|
2022
Q4 | $643K | Buy |
13,818
+8,605
| +165% | +$392K | ﹤0.01% | 2124 |
|
|
2022
Q3 | $270K | Buy |
+5,213
| New | +$305K | ﹤0.01% | 2540 |
|
|
2021
Q3 | – | Sell |
-4,924
| Closed | -$217K | – | 3032 |
|
|
2021
Q2 | $217K | Buy |
+4,924
| New | +$241K | ﹤0.01% | 2767 |
|
|
2020
Q4 | – | Sell |
-5,271
| Closed | -$241K | – | 2999 |
|
|
2020
Q3 | $241K | Sell |
5,271
-1,266
| -19% | -$61.3K | ﹤0.01% | 1972 |
|
|
2020
Q2 | $328K | Sell |
6,537
-15,074
| -70% | -$780K | 0.01% | 1544 |
|
|
2020
Q1 | $1.11M | Buy |
21,611
+9,674
| +81% | +$516K | 0.03% | 680 |
|
|
2019
Q4 | $737K | Sell |
11,937
-22,561
| -65% | -$1.4M | ﹤0.01% | 1520 |
|
|
2019
Q3 | $2.07M | Buy |
34,498
+27,303
| +379% | +$2.03M | 0.02% | 833 |
|
|
2019
Q2 | $607K | Sell |
7,195
-3,209
| -31% | -$289K | 0.01% | 1548 |
|
|
2019
Q1 | $994K | Sell |
10,404
-11,887
| -53% | -$1.07M | 0.01% | 1113 |
|
|
2018
Q4 | $1.58M | Buy |
22,291
+11,987
| +116% | +$919K | 0.02% | 754 |
|
|
2018
Q3 | $881K | Sell |
10,304
-7,686
| -43% | -$770K | 0.01% | 1048 |
|
|
2018
Q2 | $2.08M | Sell |
17,990
-6,187
| -26% | -$617K | 0.03% | 609 |
|
|
2018
Q1 | $1.96M | Sell |
24,177
-2,289
| -9% | -$176K | 0.03% | 583 |
|
|
2017
Q4 | $1.55M | Buy |
+26,466
| New | +$1.33M | 0.03% | 650 |
|
|
2017
Q1 | – | Sell |
-8,098
| Closed | -$271K | – | 1617 |
|
|
2016
Q4 | $271K | Sell |
8,098
-787
| -9% | -$22.6K | 0.01% | 1215 |
|
|
2016
Q3 | $236K | Buy |
+8,885
| New | +$206K | 0.02% | 837 |
|
|
2016
Q2 | – | Sell |
-8,000
| Closed | -$235K | – | 1167 |
|
|
2016
Q1 | $235K | Sell |
8,000
-4,532
| -36% | -$126K | 0.02% | 935 |
|
|
2015
Q4 | $414K | Buy |
+12,532
| New | +$408K | 0.05% | 634 |
|
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
Squarepoint's ENTA Position: Q2 2026 in Review
Squarepoint sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 13,567 shares — an estimated $171K sold.
Squarepoint first reported a position in ENTA in Q4 2015 and held it in 25 quarters. The position peaked at $2.08M in Q2 2018. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Squarepoint reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 13,567 Enanta Pharmaceuticals shares in Q2 2026, an estimated $171K.
- Squarepoint first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 25 quarters.
- Squarepoint's Enanta Pharmaceuticals position peaked at $2.08M in Q2 2018.
- 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.